Non-CME educational program for U.S. HCPs reviewing HDV etiology, epidemiology, disease progression, screening/diagnosis, care-cascade gaps, and a hypothetical patient case, with an overview of bulevirtide as an FDA-approved treatment option for chronic HDV in eligible adults.

“Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.”

Industry Supporter: Gilead Sciences, Inc.

This program explores the risks associated with MASLD/MASH, why early screening for liver fibrosis is needed in at-risk patients like those with obesity, and why metabolic drivers should be addressed as part of MASH care.

Industry Supporter: Boehringer Ingelheim Pharmaceuticals, Inc.

Join us as we explore the changing chronic hepatitis B landscape, with a focus on how emerging approaches to disease evaluation can optimize patient outcomes. This session will examine evolving concepts in comprehensive assessment that may influence testing and treatment decisions.

Industry Supporter: GlaxoSmithKline, LLC

 Scientific advances are expanding the conversation around functional cure and the future of chronic hepatitis B management. Join expert faculty to review unmet needs in CHB management; gain insights on patient evaluation and monitoring; and explore emerging scientific developments in the CHB treatment landscape that may inform future clinical practice.

Industry Supporter: GSK Medical Affairs

Steatotic liver disease represents a substantial clinical and public health burden. This program will examine the role of non-invasive tests in the identification and referral of patients, explore approaches to enhancing early intervention and review the evidence supporting fibrosis regression as a key objective to improve patient outcomes.

Industry Supporter: GSK

Join us for an informative presentation on Wilson disease. This promotional peer-to-peer discussion will explore unmet needs in Wilson disease, strategies for long-term management, and the role of an approved treatment option.

Industry Supporter: Orphalan Inc.

Highlight expert perspectives on diagnosing IgG4-RD and its manifestations, including type 1 AIP and IgG4-related sclerosing cholangitis. Review Importance of assessing patients with IgG4-RD for extra-GI manifestations and highlight clinical trial data.

Industry Supporter: Amgen

CHD remains underdiagnosed, with patient identification historically limited by therapeutic options. Yet it’s the most aggressive form of viral hepatitis, with the worst outcomes when untreated. Join an interactive session with leading hepatologists and a person living with CHD to explore the diagnostic journey, care gaps, and evolving treatment landscape. 

Industry Supporter: Mirum Pharmaceuticals

Join the conversation at PER's hybrid CME satellite symposium! This interactive format will feature emerging clinical evidence via real patient cases and decision points, covering treatment selection and multidisciplinary strategies across the HCC and BTC continuum.
 

• CE: 1.5 CME Hours
• Supported by: AstraZeneca
• Organized by: Physicians' Education Resource, LLC (PER)
• For more information and to register, visit: https://www.gotoper.com/courses/show-me-the-data-immunotherapy-across-the-hepatobiliary-cancer-continuumfrom-embolization-eligible-hcc-to-advanced-biliary-tract-cancers?utm_medium=website&utm_source=thirdparty&utm_campaign=assoc_website